TriLink Awarded SBIR Phase II Grant: Chemical Determinants of DNA Ligase Fidelity
Complete the form below to unlock access to ALL audio articles.
In these continued studies, the utility of chemically modified components will be explored as a potential means of enhancing ligation fidelity in a variety of advanced applications that employ DNA ligase, including SNP detection, proximity ligation, and sequencing by ligation. This is the fourth Phase II grant TriLink has been awarded and it will be funded through February 2012.
Dr. Natasha Paul, lead biologist, commented, “This grant demonstrates TriLink’s continued focus on solving molecular biology problems through chemistry.”
TriLink’s CEO, Richard Hogrefe stated, “TriLink is first and foremost a research and development team. We are committed to our science, as well as supporting our customers’ scientific advancements, and are confident we will soon offer a number of novel ligation products to compliment our CleanAmp™ PCR line of products.”
